The technological revolution of diabetes
Artificial pancreas is now a reality: this is the conclusion of the meeting with the press “Meet the Scientist. The technological revolution of diabetes” organized by Medtronic last September 27th at MoMeC, the prestigious meeting center in the heart of Rome, owned by Fiera Milano Congressi.
Francine Kaufman, the scientist who first had the idea of creating an artificial pancreas, chief medical officer and vice president of Medtronic Diabetes, outlined the clinical study of the new Medtronic hybrid closed loop system. A system that has allowed patients to achieve a lower glycemic variability and a reduction in glycated haemoglobin (one of the most important parameters to evaluate the long-term effects of the therapy), with a greater safety profile. The results of this experiment have been published in these days in the Journal of American Medical Association (JAMA).
The near future will see the creation of the artificial pancreas with the introduction of an increasingly greater “automation.” The new developments of this technology are of great importance because they can predict and prevent hypoglycemic episodes and the consequent non-adherence to therapy from the patient, also avoiding hospitalizations related to this factor with a clear money saving for the National Health Service. However, this system, can be exclusively used in people with type I diabetes (in Italy 250,000, 20,000 of which up to 18 years), in which the pancreas does not produce enough insulin forcing the patient to inject it daily.
Some of the guest speakers at MoMeC were Claudio Tubili, chief of the Diabetes Unit at San Camillo-Forlanini Hospital in Rome, and Fortunato Lombardo, university researcher at the OU of Paediatric Clinic at the University Hospital G. Martino di Messina and coordinator of the Diabetes Study Group of the Italian Society of paediatric Diabetes.